Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00206115
Status:
COMPLETED
Last Update Posted:
2013-01-04
First Post:
2005-09-14
Brief Title:
SR-Registration Study 1 ROW Efficacy and Safety of Seroquel in the Treatment of Patients With Schizophrenia
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 6-week Multicenter Double-blind Double-dummy Randomized Comparison of the Efficacy Safety of Sustained-Release Formulation Quetiapine Fumarate SEROQUEL Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this 6-week study is to determine whether treatment with Seroquel Sustained Release SR is more effective than placebo in the treatment of acute schizophrenia
PLEASE NOTE Seroquel SR and Seroquel XR refer to the same formulation The SR designation was changed to XR after consultation with FDA
PLEASE NOTE Seroquel SR and Seroquel XR refer to the same formulation The SR designation was changed to XR after consultation with FDA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None